{
    "ticker": "SRNE",
    "name": "Sorrento Therapeutics, Inc.",
    "description": "Sorrento Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of proprietary therapeutics to treat cancer, pain, and other diseases. Founded in 2006, Sorrento is driven by a mission to provide innovative solutions for patients suffering from serious medical conditions. The company is known for its extensive pipeline of products, including monoclonal antibodies, cell therapies, and small molecules, which are designed to target a range of diseases with high unmet medical needs. Sorrento's lead asset, COVI-DROPS, is a nasal spray formulation aimed at preventing and treating COVID-19, showcasing the company's commitment to addressing urgent health challenges. With a strong emphasis on research and development, Sorrento collaborates with various research institutions and pharmaceutical partners to advance its therapeutic candidates through clinical trials. The company also leverages its proprietary technology platforms, such as the G-MAB library, to discover and develop novel antibodies. Sorrento Therapeutics is dedicated to improving patient outcomes and enhancing the quality of life for individuals affected by debilitating diseases, positioning itself as a key player in the biopharmaceutical landscape.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2006",
    "website": "https://www.sorrentotherapeutics.com",
    "ceo": "Henry Ji",
    "social_media": {
        "twitter": "https://twitter.com/SorrentoThera",
        "linkedin": "https://www.linkedin.com/company/sorrento-therapeutics/"
    },
    "investor_relations": "https://investors.sorrentotherapeutics.com",
    "key_executives": [
        {
            "name": "Henry Ji",
            "position": "CEO"
        },
        {
            "name": "Jing Wu",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "COVI-DROPS",
                "ZTlido",
                "Abivertinib"
            ]
        }
    ],
    "seo": {
        "meta_title": "Sorrento Therapeutics, Inc. | Innovative Therapeutics for Cancer and Pain",
        "meta_description": "Explore Sorrento Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for cancer, pain, and other diseases.",
        "keywords": [
            "Sorrento Therapeutics",
            "Biotechnology",
            "Pharmaceuticals",
            "COVI-DROPS",
            "Cancer Treatment",
            "Pain Management"
        ]
    },
    "faq": [
        {
            "question": "What is Sorrento Therapeutics known for?",
            "answer": "Sorrento Therapeutics is known for developing innovative therapeutics for cancer, pain, and other serious diseases."
        },
        {
            "question": "Who is the CEO of Sorrento Therapeutics?",
            "answer": "Henry Ji is the CEO of Sorrento Therapeutics, Inc."
        },
        {
            "question": "Where is Sorrento Therapeutics headquartered?",
            "answer": "Sorrento Therapeutics is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are some key products of Sorrento Therapeutics?",
            "answer": "Key products include COVI-DROPS, ZTlido, and Abivertinib."
        },
        {
            "question": "When was Sorrento Therapeutics founded?",
            "answer": "Sorrento Therapeutics was founded in 2006."
        }
    ],
    "competitors": [
        "MRNA",
        "NVAX",
        "BNTX",
        "VRTX"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "ABBV",
        "JNJ"
    ]
}